CytomX hires Hoyoung Huh to chair board
This article was originally published in Scrip
CytomX Therapeutics, a biotechnology company developing monoclonal antibody therapies, has appointed Dr Hoyoung Huh chair of the board of directors. Dr Huh currently serves as chair of Geron Corporation, and on the boards of Addex Pharmaceuticals and BayBio. He was previously CEO, president and chair of BiPar Sciences, which was acquired by Sanofi in 2009. Former CytomX chair Dr Charles Homcy, venture partner at Third Rock Ventures, will continue to serve on the board.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.